Equities
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,493.00
  • Today's Change10.00 / 0.40%
  • Shares traded1.44m
  • 1 Year change-9.82%
  • Beta0.8051
Data delayed at least 15 minutes, as of Jul 03 2025 07:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kyowa Kirin Co Ltd is a Japan-based company engaged in the manufacture and sale of medical drugs. The Company operates in Pharmaceuticals business segment. The Company engages in the research, development, manufacture, sale, and import & export of prescription pharmaceuticals. The Company has drug discovery technologies in antibody therapeutics and hematopoietic stem cell gene therapy. Its development pipeline includes AMG531 for aplastic anemia untreated with immunosuppressive therapy, KHK4083/AMG 451 for moderate to severe atopic dermatitis, KHK4083/AMG 451 for moderate to severe asthma, and KK2845 for acute myeloid leukemia and others. In addition, through its subsidiaries, the Company develops, manufactures, markets, and contracts out biosimilar pharmaceuticals, and engages in wholesale and retail sales and insurance agency business. The Company operates in Japan and overseas.

  • Revenue in JPY (TTM)494.71bn
  • Net income in JPY51.40bn
  • Incorporated1949
  • Employees5.67k
  • Location
    Kyowa Kirin Co LtdOtemachi Financial City Grand Cube1-9-2, Ote-machiCHIYODA-KU 100-0004JapanJPN
  • Phone+81 352057200
  • Fax+81 352057182
  • Websitehttps://www.kyowakirin.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Tsumura & Co181.09bn32.43bn267.43bn4.27k8.160.8785.851.48427.12427.122,385.353,968.060.40580.722.7342,390,680.007.745.539.756.8550.0249.3919.0614.502.62--0.176631.6520.058.0094.1018.6923.0716.27
Hisamitsu Pharmaceutical Co Inc156.01bn21.76bn300.89bn2.80k13.551.0610.511.93295.53295.532,116.233,794.070.46442.983.4755,736,340.006.644.347.774.9958.4657.8314.3010.323.84--0.013650.2910.092.0455.763.0829.890.7127
Sumitomo Pharma Co Ltd398.83bn23.63bn359.30bn3.83k15.182.127.300.900959.4959.491,003.88426.590.48341.465.96104,079,300.002.86-5.495.29-8.4961.5367.885.93-13.240.66062.460.6496--26.79-3.75107.50-10.32-0.4856--
Rohto Pharmaceutical Co Ltd308.63bn31.01bn487.71bn9.14k15.241.7911.061.58135.51135.511,349.221,151.040.80372.474.4633,751,640.008.068.5910.7811.7056.6857.7810.0310.571.65--0.192421.1213.9510.380.226315.0110.4222.59
Santen Pharmaceutical Co Ltd300.00bn36.25bn565.60bn3.85k15.961.9710.511.89103.60103.60858.37838.520.71012.723.8877,943,360.008.493.9410.754.9357.0158.9711.956.011.99--0.107271.86-0.64944.4336.098.943.615.92
Ono Pharmaceutical Co Ltd486.87bn50.05bn778.46bn4.29k14.650.937210.101.60106.52106.521,036.361,665.600.49242.403.79113,569,200.005.0710.785.8512.3769.6173.2310.3021.232.56142.590.156936.33-3.1410.73-60.89-3.47-18.6612.20
Eisai Co Ltd789.40bn46.43bn1.19tn13.51k24.901.3713.521.51163.81163.812,784.172,982.520.56780.86444.4758,448,100.003.463.814.685.1478.6277.466.096.441.37--0.17898.016.422.569.49-17.54-14.480.00
Kyowa Kirin Co Ltd494.71bn51.40bn1.31tn5.67k25.511.5617.022.6497.3497.34939.971,588.590.47451.783.9287,266,360.004.936.375.757.2573.4075.1310.3914.652.7117.520.0046.3812.0610.14-26.269.7137.716.67
Shionogi & Co Ltd438.27bn170.44bn2.27tn4.96k12.741.5911.925.18200.28200.28514.991,600.970.29690.9793.6188,449,650.0011.4912.1712.6913.7485.4484.9138.6838.306.13--0.015827.870.73255.625.196.8834.6612.30
Astellas Pharma Inc1.91tn50.75bn2.52tn13.64k50.501.6510.081.3227.5627.561,062.16845.250.55361.283.28140,168,800.001.473.052.224.4581.7481.152.655.420.85164.000.3824131.4219.258.01197.72-23.64-5.9413.09
Otsuka Holdings Co Ltd2.39tn350.74bn3.75tn35.34k10.611.388.091.57650.78650.784,433.965,000.590.67012.295.0367,722,650.009.925.9112.387.2772.2069.1814.819.891.44--0.085932.9315.4210.78182.1321.9615.323.71
Daiichi Sankyo Co Ltd1.89tn295.76bn6.25tn19.77k21.163.7917.153.31155.87155.87994.10869.690.54540.87264.2495,434,150.008.555.7210.877.1177.9672.1515.6811.031.85--0.087649.5717.7713.9544.4717.7729.0120.79
Data as of Jul 03 2025. Currency figures normalised to Kyowa Kirin Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

12.96%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 05 Jun 202517.34m3.30%
The Vanguard Group, Inc.as of 04 Jun 20258.96m1.71%
Nikko Asset Management Co., Ltd.as of 06 Jun 20258.68m1.65%
Daiwa Asset Management Co. Ltd.as of 30 May 20257.93m1.51%
BlackRock Fund Advisorsas of 05 Jun 20255.80m1.10%
Goldman Sachs Asset Management Co., Ltd. (Japan)as of 31 Mar 20255.50m1.05%
Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Jun 20254.59m0.87%
Norges Bank Investment Managementas of 31 Dec 20244.48m0.85%
Geode Capital Management LLCas of 26 Jun 20252.58m0.49%
BlackRock Advisors (UK) Ltd.as of 06 Jun 20252.23m0.42%
More ▼
Data from 31 Dec 2024 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.